Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 21, 2014; 20(47): 17976-17984
Published online Dec 21, 2014. doi: 10.3748/wjg.v20.i47.17976
Published online Dec 21, 2014. doi: 10.3748/wjg.v20.i47.17976
Table 3 Patients’ baseline characteristics according to the MOSAIC and No. 16968 trials
| FOLFOX4 (n = 1123) | XELOX (n = 944) | |
| Male, % | 56.1 | 54 |
| Age, yr | 61 | 61 |
| Depth of invasion, % | ||
| T1-2 | 4.5 | 11 |
| T3 | 76 | 74 |
| T4 | 19 | 15 |
| TX | 0.5 | < 1 |
| Histology, % | ||
| Differentiated | 83.2 | 81 |
| Poorly differentiated | 12.6 | 15 |
| Unknown | 4.2 | 3 |
- Citation: Wen F, Yao K, Du ZD, He XF, Zhang PF, Tang RL, Li Q. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials. World J Gastroenterol 2014; 20(47): 17976-17984
- URL: https://www.wjgnet.com/1007-9327/full/v20/i47/17976.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i47.17976